Results 21 to 30 of about 2,351 (180)
Epicutaneous immunotherapy protects cashew-sensitized mice from anaphylaxis. [PDF]
Allergy, 2021 AbstractBackgroundThe prevalence of tree nut allergy has increased worldwide, and cashew has become one of the most common food allergens. More critically, cashew allergy is frequently associated with severe anaphylaxis. Despite the high medical need, no approved treatment is available and strict avoidance and preparedness for prompt treatment of ...
Pelletier B +14 more
europepmc +4 more sources
Epicutaneous immunotherapy for the treatment of peanut allergy. [PDF]
AllergyPeanut allergy treatment options remain limited, but novel approaches are being studied, including epicutaneous immunotherapy (EPIT). EPIT uses the cutaneous immune system to promote tolerance to food allergens. Viaskin Peanut, an approach to EPIT in late-stage clinical development uses an occlusive patch with a condensation chamber that enables ...
Ravindran M +5 more
europepmc +3 more sources
Epicutaneous Immunotherapy for Aeroallergen and Food Allergy. [PDF]
Curr Treat Options Allergy, 2014 IgE-mediated allergies today affect up to 30 % of the population in industrialized countries. Allergen immunotherapy is the only disease-modifying treatment option with a long-term effect. However, very few patients (
Senti G, von Moos S, Kündig TM.
europepmc +4 more sources
Laser-facilitated epicutaneous immunotherapy to IgE-mediated allergy. [PDF]
J Control Release, 2016 Allergen specific immunotherapy has been shown to be the only effective treatment for long-lasting clinical benefit to IgE-mediated allergic diseases, but a fewer than 5% of patients choose the treatment because of inconvenience and a high risk of anaphylaxis.
Kumar MNK, Zhou C, Wu MX.
europepmc +4 more sources
Food allergy immunotherapy: Oral immunotherapy and epicutaneous immunotherapy [PDF]
Allergy, 2020 AbstractIgE‐mediated food allergy remains a significant and growing problem across the globe. Of the various treatment modalities, oral immunotherapy (OIT) and epicutaneous immunotherapy (EPIT) have been the best studied. Across various studies of OIT for egg, milk, and peanut allergy, strong levels of desensitization have been shown.
Edwin H. Kim, Arvil Wesley Burks
openaire +2 more sources
Iranian Journal of Allergy, Asthma and Immunology, 2022 Allergen-specific immunotherapy (AIT) involves administering allergen extracts. It is used to desensitize allergic patients. Herbal allergen extracts that are optimum in efficacy and fewest in side effects are still challenging to produce.
Soheila Asoudeh Moghanloo +4 more
doaj +1 more source
Delivery of allergen powder for safe and effective epicutaneous immunotherapy. [PDF]
J Allergy Clin Immunol, 2020 More effective and safer immunotherapies to manage peanut allergy are in great demand despite extensive investigation of sublingual/oral immunotherapy and epicutaneous immunotherapy (EPIT) currently in the clinics.We sought to develop a powder-laden, dissolvable microneedle array (PLD-MNA) for epidermal delivery of powdered allergens and to evaluate ...
Yu Y, Kiran Kumar MN, Wu MX.
europepmc +4 more sources
Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis [PDF]
, 2017 Background: The European Academy of Allergy and Clinical Immunology (EAACI) is developing Guidelines for Allergen Immunotherapy (AIT) for IgE-mediated Food Allergy.
Dhami, Sangeeta +2 more
core +9 more sources
Oral Immunotherapy for Children with Cow’s Milk Allergy
Pathogens, 2021 Cow’s milk allergy (CMA) is one of the most common IgE-dependent food allergies in children. Some children develop severe and persistent CMA, with near-fatal reactions after exposure to trace amounts of cow’s milk (CM).
Mika Ogata, Jun Kido, Kimitoshi Nakamura
doaj +1 more source
Positive and negative AIT trials: What makes the difference? [PDF]
, 2018 Background: Allergen immunotherapy has proven to be efficacious in allergic rhinitis and asthma. However, results from randomised clinical trials may vary substantially. Clinical trials may unexpectedly fail.
Gerth van Wijk, R. (Roy)
core +6 more sources